salvia miltiorrhiza + somatostatin

Salvia miltiorrhiza + somatostatin is a combination therapy consisting of Salvia miltiorrhiza (a traditional Chinese medicinal herb, also known as Danshen) and somatostatin (a peptide hormone and pharmaceutical drug). This combination has been studied primarily for the treatment of severe acute pancreatitis. Somatostatin acts by inhibiting the secretion of various hormones and digestive enzymes, thereby reducing pancreatic exocrine activity and inflammation. Salvia miltiorrhiza contains bioactive compounds with anti-inflammatory, antioxidant, immunomodulatory, and cardiovascular protective effects. Clinical studies suggest that combining these agents can improve outcomes in acute pancreatitis by reducing inflammatory cytokines (such as TNF-α and IL-6), improving organ function scores, lowering rates of complications like pancreatic sepsis or multiple organ dysfunction syndrome, and decreasing mortality compared to standard care or monotherapy. The mechanism involves both direct inhibition of inflammatory mediators by Salvia miltiorrhiza’s constituents (e.g., via PI3K/Akt/JAK/STAT pathways) and suppression of pancreatic secretions by somatostatin.